查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771691

美国胃癌诊断市场规模、份额、趋势分析报告：按产品、疾病类型、最终用途、细分市场预测，2025-2033

U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国胃癌诊断市场摘要

美国胃癌诊断市场规模预计在2024年达到4.8909亿美元，预计到2033年将达到8.972亿美元，2025年至2033年的复合年增长率为7.08%。由于诊断技术的进步、患者认知度和教育水平的提高以及新兴市场医疗基础设施的不断完善，美国胃癌诊断市场正在不断扩张。根据美国癌症协会 (ACS) 的数据，预计2024年美国新患者和死亡人数分别为26,890例和10,880例；2025年新患者和死亡人数分别为30,300例和10,780例。

液态切片、次世代定序(NGS) 和基于人工智慧的成像等技术创新正在推动市场成长。这些工具能够实现更早的检测、更精准的分期和更清晰的肿瘤生物学特性描述，从而製定更个人化和有效的治疗方案。窄带成像和共聚焦雷射内视镜等先进的内视镜技术提高了诊断准确性和患者预后。分子诊断的整合还能实现基于基因图谱的标靶治疗。技术进步正在推动市场需求，因为医疗保健提供者和研究人员正在寻求更精准、侵入性更小的治疗方法，与传统方法相比，能够提供更快的结果、更高的灵敏度和更少的患者不适感。

由政府、非政府组织和医疗保健提供者主导的公众意识提升宣传活动和教育计划正在提高人们对胃癌状和风险因素的认识，进一步推动市场成长。例如，胃癌希望是一个全国性的非营利组织，它将在 2025 年 5 月的 ASCO 年会上发挥关键作用，该组织透过宣传、教育、患者支持和国家立法伙伴关係来促进胃癌和胃食道癌的早期发现、治疗和认识。这种认识的提高正在鼓励人们更多地参与早期咨询和筛检计划。此外，提高健康素养和获取线上医疗资讯使患者能够及时寻求诊断和适当的治疗。随着患者和看护者变得更加积极主动，对准确和可及的诊断服务的需求也日益增加。这种趋势在新兴国家很重要，这些国家的宣导活动正在缩小医疗保健利用的差距，刺激诊断技术市场的成长。

医疗基础设施的不断扩大是美国胃癌诊断市场发展的驱动因素之一。美国对医疗基础设施的持续投资，尤其是在医疗资源匮乏和农村地区，改善了人们获得诊断服务的机会，包括内视镜检查和先进的胃癌影像技术。联邦政府资助的计画和不断扩大的医院网络旨在解决差异，使胃癌高危险群（如亚裔美国人和西班牙裔社区）能够更早发现并取得更好的治疗效果，因为这些人群的胃癌发病率相对较高。这些措施透过增加对诊断工具的需求来支持市场的成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国胃癌诊断市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/辅助市场展望。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国胃癌诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国胃癌诊断市场：产品评估与趋势分析

  • 2024年及2033年的产品市场占有率
  • 细分仪表板
  • 美国胃癌诊断市场：产品变化分析
  • 美国胃癌诊断市场规模及趋势分析（依产品，2021-2033）
  • 2021-2033年美国胃癌诊断市场收益估计及预测
  • 试剂和耗材
  • 装置

第五章美国胃癌诊断市场：依疾病类型估计与趋势分析

  • 2024 年及 2033 年各疾病类型的市场占有率
  • 细分仪表板
  • 美国胃癌诊断市场：疾病类型展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 腺癌
  • 胃淋巴瘤
  • 其他的

第六章美国胃癌诊断市场：最终用途估计与趋势分析

  • 2024年及2033年最终用途市场占有率
  • 细分仪表板
  • 美国胃癌诊断市场：按最终用途分類的展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 医院
  • 诊断实验室
  • 诊断影像

第七章美国胃癌诊断市场：各国估计与趋势分析

  • 2024 年及 2033 年各国市场
  • 各国市场仪表板
  • 美国市场概述
  • 市场规模、预测趋势分析，2021-2033年：
  • 美国
    • 主要国家趋势
    • 法规结构/报销
    • 竞争场景

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Illumina, Inc.
    • Guardant Health
    • Natera, Inc
    • GE Healthcare.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Freenome Holdings Inc
    • Exact Sciences Corporation
    • PathAI
Product Code: GVR-4-68040-632-5

U.S. Gastric Cancer Diagnostics Market Summary

The U.S. gastric cancer diagnostics market size was estimated at USD 489.09 million in 2024 and is projected to reach 897.20 million by 2033, and growing at a CAGR of 7.08% from 2025 to 2033. The U.S. gastric cancer diagnostics market is expanding due to advancements in diagnostic technologies, increasing awareness and patient education, and the expansion of healthcare infrastructure in emerging markets. According to the American Cancer Society (ACS) in 2024, gastric cancer accounted for 26,890 new cases and 10,880 deaths in the U.S. In addition, 30,300 new cases and 10,780 deaths are estimated in the U.S. for the year 2025.

Technological innovations such as liquid biopsies, next-generation sequencing (NGS), and AI-based imaging are propelling the market growth. These tools enable early detection, improved staging, and better characterization of tumor biology, leading to more personalized and effective treatment plans. Advanced endoscopy techniques, like narrow-band imaging and confocal laser endomicroscopy, enhance diagnostic accuracy and patient outcomes. Integration of molecular diagnostics also allows for targeted therapies based on genetic profiles. As healthcare providers and researchers push for more precise, less invasive methods, technological progress boosts market demand, offering faster results, better sensitivity, and reduced patient discomfort compared to traditional methods.

Public awareness campaigns and educational initiatives led by governments, NGOs, and healthcare providers are further fueling market growth by improving recognition of gastric cancer symptoms and risk factors. One such example is Hope for Stomach Cancer, a national nonprofit organization that will play a key role at the May 2025 ASCO Annual Meeting, advancing early detection, treatment, and awareness of stomach and gastroesophageal cancers through advocacy, education, patient support, and national legislative partnerships. This increased awareness is prompting earlier medical consultations and higher participation in screening programs. Moreover, the rise in health literacy and access to online medical information empowers patients to seek timely diagnosis and appropriate care. As patients and caregivers become more proactive, the demand for accurate and accessible diagnostic services grows. This trend is vital in emerging economies, where awareness efforts are narrowing the gap in healthcare utilization and fueling market growth for diagnostic technologies.

The expansion of healthcare infrastructure associated with developing nations is one of the drivers in the U.S. gastric cancer diagnostics market through a different lens, namely, health equity and outreach. In the U.S., ongoing investments in healthcare infrastructure, especially in underserved and rural areas, are improving access to diagnostic services, including endoscopy and advanced imaging for gastric cancer. Federally funded programs and hospital network expansions aim to bridge disparities, enabling earlier detection and better outcomes in high-risk populations such as Asian American and Hispanic communities, where gastric cancer prevalence is comparatively higher. These efforts support market growth by increasing demand for diagnostic tools.

U.S. Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. gastric cancer diagnostics market report based on product, disease type, end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents & Consumables
  • Instruments
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adenocarcinoma
  • Gastric lymphoma
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic imaging

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Type
    • 1.2.3. End use
    • 1.2.4. Country scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Gastric Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Gastric Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Gastric Cancer Diagnostics Market: Product Movement Analysis
  • 4.4. U.S. Gastric Cancer Diagnostics Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 4.5. U.S. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reagents & consumables
    • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Instruments
    • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

  • 5.1. Disease Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Gastric Cancer Diagnostics Market by Disease Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Adenocarcinoma
    • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Gastric lymphoma
    • 5.6.1. Gastric lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Gastric Cancer Diagnostics Market: End use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Gastric Cancer Diagnostics Market by End use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Diagnostic imaging
    • 6.7.1. Diagnostic imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2024 & 2033
  • 7.2. Country Market Dashboard
  • 7.3. U.S. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework/Reimbursement
    • 7.5.3. Competitive scenario
    • 7.5.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Illumina, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Guardant Health
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Natera, Inc
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GE Healthcare.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Thermo Fisher Scientific Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. QIAGEN
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Freenome Holdings Inc
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Exact Sciences Corporation
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. PathAI
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 3 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 4 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Gastric Cancer Diagnostics market: market outlook
  • Fig. 10 U.S. Gastric Cancer Diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Gastric Cancer Diagnostics market driver impact
  • Fig. 16 U.S. Gastric Cancer Diagnostics market restraint impact
  • Fig. 17 U.S. Gastric Cancer Diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. Gastric Cancer Diagnostics market: Product movement analysis
  • Fig. 19 U.S. Gastric Cancer Diagnostics market: Product outlook and key takeaways
  • Fig. 20 Reagents & consumables market estimates and forecasts, 2021 - 2033
  • Fig. 21 Instruments market estimates and forecasts,2021 - 2033
  • Fig. 22 U.S. Gastric Cancer Diagnostics Market: Disease type movement analysis
  • Fig. 23 U.S. Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
  • Fig. 24 Adenocarcinoma market estimates and forecasts, 2021 - 2033
  • Fig. 25 Gastric lymphoma market estimates and forecasts, 2021 - 2033
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033
  • Fig. 27 U.S. Gastric Cancer Diagnostics Market: End use movement analysis
  • Fig. 28 U.S. Gastric Cancer Diagnostics market: End use outlook and key takeaways
  • Fig. 29 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 30 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 31 Diagnostic imaging market estimates and forecasts, 2021 - 2033
  • Fig. 32 U.S. Gastric Cancer Diagnostics market: Country movement analysis
  • Fig. 33 U.S. Gastric Cancer Diagnostics market: Country outlook and key takeaways
  • Fig. 34 U.S. Gastric Cancer Diagnostics market share and leading players
  • Fig. 35 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 36 Market share of key market players- U.S. Gastric Cancer Diagnostics market